Functional comparison of induced pluripotent stem cell- and blood-derived GPIIbIIIa deficient platelets

PLoS One. 2015 Jan 21;10(1):e0115978. doi: 10.1371/journal.pone.0115978. eCollection 2015.

Abstract

Human induced pluripotent stem cells (hiPSCs) represent a versatile tool to model genetic diseases and are a potential source for cell transfusion therapies. However, it remains elusive to which extent patient-specific hiPSC-derived cells functionally resemble their native counterparts. Here, we generated a hiPSC model of the primary platelet disease Glanzmann thrombasthenia (GT), characterized by dysfunction of the integrin receptor GPIIbIIIa, and compared side-by-side healthy and diseased hiPSC-derived platelets with peripheral blood platelets. Both GT-hiPSC-derived platelets and their peripheral blood equivalents showed absence of membrane expression of GPIIbIIIa, a reduction of PAC-1 binding, surface spreading and adherence to fibrinogen. We demonstrated that GT-hiPSC-derived platelets recapitulate molecular and functional aspects of the disease and show comparable behavior to their native counterparts encouraging the further use of hiPSC-based disease models as well as the transition towards a clinical application.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Blood Platelets / cytology*
  • Blood Platelets / metabolism*
  • Cell Adhesion
  • Cells, Cultured
  • Female
  • Fibrinogen / metabolism
  • Humans
  • Induced Pluripotent Stem Cells / cytology*
  • Induced Pluripotent Stem Cells / metabolism
  • Integrin alpha2 / genetics
  • Integrin alpha2 / metabolism
  • Models, Biological
  • Thrombasthenia / genetics
  • Thrombasthenia / pathology*

Substances

  • ITGA2B protein, human
  • Integrin alpha2
  • Fibrinogen

Grants and funding

This work was supported by grants from the European Research Council (ERC261053 to KLL (http://erc.europa.eu)); the Deutsche Forschungsgemeinschaft (Research Unit 923, Mo2217/1-1 to AM, La1238 3-1/4-1 to KLL, and Si1747/1-1 to DS; SFB914 and TP-A3&B2&Z1 to SM (http://www.dfg.de)); the Framework Programme 7 of the European Union (PRESTIGE to SM (http://www.prestige-fp7.eu)); and the Deutsches Zentrum für Herz-Kreislauf-Forschung (German Centre for Cardiovascular Research), partner site Munich Heart Alliance (to AM, KLL, and SM (dzhk.de)). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.